Education
About Us
Working with TipRanks
Follow Us
Lexicon Pharmaceuticals (LXRX)
NASDAQ:LXRX
LXRX Stock Chart & Stats
$1.56
-$0.12(-12.49%)
At close: 4:00 PM EST
$1.56
-$0.12(-12.49%)
Day’s Range― - ―
52-Week Range$0.28 - $1.66
Previous CloseN/A
Volume2.02M
Average Volume (3M)2.74M
Market Cap
$483.32M
Enterprise Value$266.27M
Total Cash (Recent Filing)$115.95M
Total Debt (Recent Filing)$64.94M
Price to Earnings (P/E)―
Beta2.26
Next Earnings
Mar 18, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding363,398,860
10 Day Avg. Volume3,297,817
30 Day Avg. Volume2,735,746
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.62
Price to Sales (P/S)7.60
P/FCF Ratio-1.31
Enterprise Value/Market Cap0.55
Enterprise Value/Revenue3.76
Enterprise Value/Gross Profit3.79
Enterprise Value/Ebitda-4.61
Forecast
1Y Price Target
$3.97Price Target Upside154.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPreclinical studies in HCM animal models indicate disease-modifying potential, expected to translate to ongoing clinical trials.
Drug EfficacySotagliflozin demonstrated reduced risk of cardiovascular death, major adverse cardiovascular events, and hospitalizations for heart failure, particularly among older adults.
Regulatory DevelopmentsThe agreement with the FDA to leverage the Steno 1 trial is encouraging from a regulatory perspective.
Bears Say
Clinical Trial AdherenceParticipants in the 20 mg arm were the least adherent, potentially driven by increased adverse events and treatment discontinuations.
Clinical Trial OutcomesThe study missed the prespecified primary endpoint of ADPS change from baseline to week 8 due to lack of dose response in the 20 mg arm.
Regulatory ConcernsConcerns from the FDA around Zynquista revolve around diabetic ketoacidosis rates.
Lexicon Pharmaceuticals News
LXRX FAQ
What was Lexicon Pharmaceuticals’s price range in the past 12 months?
Lexicon Pharmaceuticals lowest stock price was $0.28 and its highest was $1.66 in the past 12 months.
What is Lexicon Pharmaceuticals’s market cap?
Lexicon Pharmaceuticals’s market cap is $483.32M.
When is Lexicon Pharmaceuticals’s upcoming earnings report date?
Lexicon Pharmaceuticals’s upcoming earnings report date is Mar 18, 2026 which is in 125 days.
How were Lexicon Pharmaceuticals’s earnings last quarter?
Lexicon Pharmaceuticals released its earnings results on Nov 06, 2025. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.066 by $0.026.
Is Lexicon Pharmaceuticals overvalued?
According to Wall Street analysts Lexicon Pharmaceuticals’s price is currently Undervalued.
Does Lexicon Pharmaceuticals pay dividends?
Lexicon Pharmaceuticals does not currently pay dividends.
What is Lexicon Pharmaceuticals’s EPS estimate?
Lexicon Pharmaceuticals’s EPS estimate is -0.07.
How many shares outstanding does Lexicon Pharmaceuticals have?
Lexicon Pharmaceuticals has 363,398,860 shares outstanding.
What happened to Lexicon Pharmaceuticals’s price movement after its last earnings report?
Lexicon Pharmaceuticals reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.066. Following the earnings report the stock price went up 3.623%.
Which hedge fund is a major shareholder of Lexicon Pharmaceuticals?
Currently, no hedge funds are holding shares in LXRX
Lexicon Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.97 (154.49% Upside)
$3.97 (154.49% Upside)
Hedge Fund Trend
Decreased
By 229.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 3.6%
Last 30 Days ▲ 3.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-29.35%
12-Months-Change
Fundamentals
Return on Equity
-45.92%
Trailing 12-Months
Asset Growth
-39.58%
Trailing 12-Months
Company Description
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals (LXRX) is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for the treatment of human disease. The company primarily operates in the pharmaceutical sector, specializing in drug development for conditions such as metabolic and neurodegenerative diseases. Lexicon's core products include LX9211, a treatment for diabetic neuropathic pain, and LX2761, aimed at addressing type 1 diabetes, among others.
LXRX Company Deck
LXRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive progress in revenues, R&D advancements, and strategic partnerships, while also highlighting challenges such as decreased cash reserves and the need for FDA feedback for key products. Overall, the positive aspects of the company's progress and strategic focus on future opportunities suggest a cautiously optimistic outlook.View all LXRX earnings summariesLXRX Stock 12 Month Forecast
Average Price Target
$3.97
▲(154.49% Upside)
Technical Analysis
Ownership Overview
13.05% Insiders
8.46% Mutual Funds
0.02% Other Institutional Investors
75.66% Public Companies and
Individual Investors